152 related articles for article (PubMed ID: 9074912)
1. Lisuride and bromocryptine in L-Dopa stable-responder parkinsonian patients: a comparative, double-blind evaluation of cardiopressor and neurochemical effects.
Micieli G; Martignoni E; Cavallini A; Pacchetti C; Rossi F; Horowski R; Nappi G
Funct Neurol; 1996; 11(6):317-25. PubMed ID: 9074912
[TBL] [Abstract][Full Text] [Related]
2. A study on the effect and tolerance of lisuride on Parkinson's disease.
Bayülkem K; Erişir K; Tuncel A; Bayülkem B
Adv Neurol; 1996; 69():519-30. PubMed ID: 8615174
[TBL] [Abstract][Full Text] [Related]
3. Side-effects of L-dopa on venous tone in Parkinson's disease: a leg-weighing assessment.
Wolf JP; Bouhaddi M; Louisy F; Mikehiev A; Mourot L; Cappelle S; Vuillier F; Andre P; Rumbach L; Regnard J
Clin Sci (Lond); 2006 Mar; 110(3):369-77. PubMed ID: 16302846
[TBL] [Abstract][Full Text] [Related]
4. Autonomic nervous function in de novo parkinsonian patients in basal condition and after acute levodopa administration.
Quadri R; Comino I; Scarzella L; Cacioli P; Zanone MM; Pipieri A; Bergamasco B; Chiandussi L
Funct Neurol; 2000; 15(2):81-6. PubMed ID: 10916719
[TBL] [Abstract][Full Text] [Related]
5. [Randomized study during a year of early combination of L-dopa/lisuride in Parkinson disease].
Vermersch P; Fondarai J; Petit H
Therapie; 1991; 46(6):481-6. PubMed ID: 1819154
[TBL] [Abstract][Full Text] [Related]
6. Terguride in fluctuating parkinsonian patients: a double-blind study versus placebo.
Pacchetti C; Martignoni E; Bruggi P; Godi L; Aufdembrinke B; Miltenburger C; Voet B; Nappi G
Mov Disord; 1993 Oct; 8(4):463-5. PubMed ID: 7901760
[TBL] [Abstract][Full Text] [Related]
7. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
[TBL] [Abstract][Full Text] [Related]
8. Lisuride treatment in Parkinson's disease: clinical and pharmacokinetic studies.
LeWitt PA; Burns RS; Calne DB
Adv Neurol; 1983; 37():131-40. PubMed ID: 6344586
[TBL] [Abstract][Full Text] [Related]
9. Are current recommendations to diagnose orthostatic hypotension in Parkinson's disease satisfactory?
Jamnadas-Khoda J; Koshy S; Mathias CJ; Muthane UB; Ragothaman M; Dodaballapur SK
Mov Disord; 2009 Sep; 24(12):1747-51. PubMed ID: 19562759
[TBL] [Abstract][Full Text] [Related]
10. Bromocriptine and lisuride in Parkinson disease.
Lieberman AN; Gopinathan G; Neophytides A; Leibowitz M; Walker R; Hiesiger E
Ann Neurol; 1983 Jan; 13(1):44-7. PubMed ID: 6830164
[TBL] [Abstract][Full Text] [Related]
11. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
[TBL] [Abstract][Full Text] [Related]
12. Pergolide and lisuride in advanced Parkinson's disease.
Lieberman AN; Gopinathan G; Neophytides A; Leibowitz M; Goldstein M
Adv Neurol; 1984; 40():503-7. PubMed ID: 6695627
[TBL] [Abstract][Full Text] [Related]
13. Dopamine agonists in the treatment of hyperprolactinemia. Comparison between bromocriptine and lisuride.
Stracke H; Heinlein W; Horowski R; Schatz H
Arzneimittelforschung; 1986 Dec; 36(12):1834-6. PubMed ID: 3566845
[TBL] [Abstract][Full Text] [Related]
14. A study of the cardiopressor effects of lisuride in the treatment of parkinsonism and pathological aging brain.
Micieli G; Martignoni E; Bono G; Cavallini A; Rossi F; Horowski R; Nappi G
Clin Neuropharmacol; 1989 Oct; 12(5):404-15. PubMed ID: 2692810
[TBL] [Abstract][Full Text] [Related]
15. Safety study of lazabemide (Ro19-6327), a new MAO-B inhibitor, on cardiac arrhythmias and blood pressure of patients with Parkinson's disease.
Narabayashi H; Yamaguchi T; Sugi K; Mitamura H; Mizuno Y; Nakashima M
Clin Neuropharmacol; 1999; 22(6):340-6. PubMed ID: 10626094
[TBL] [Abstract][Full Text] [Related]
16. Testosterone therapy in men with Parkinson disease: results of the TEST-PD Study.
Okun MS; Fernandez HH; Rodriguez RL; Romrell J; Suelter M; Munson S; Louis ED; Mulligan T; Foster PS; Shenal BV; Armaghani SJ; Jacobson C; Wu S; Crucian G
Arch Neurol; 2006 May; 63(5):729-35. PubMed ID: 16682542
[TBL] [Abstract][Full Text] [Related]
17. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
Im JH; Ha JH; Cho IS; Lee MC
J Neurol; 2003 Jan; 250(1):90-6. PubMed ID: 12527999
[TBL] [Abstract][Full Text] [Related]
18. Impaired cardiovascular autonomic control in newly and long-term-treated patients with Parkinson's disease: involvement of L-dopa therapy.
Bouhaddi M; Vuillier F; Fortrat JO; Cappelle S; Henriet MT; Rumbach L; Regnard J
Auton Neurosci; 2004 Nov; 116(1-2):30-8. PubMed ID: 15556835
[TBL] [Abstract][Full Text] [Related]
19. Ropinirole: new preparation. Wait for more convincing data.
Prescrire Int; 1998 Apr; 7(34):36-8. PubMed ID: 10183378
[TBL] [Abstract][Full Text] [Related]
20. Can we differentiate symptomatic and neuroprotective effects in parkinsonism? The dopamine agonist lisuride delays the need for levodopa therapy to a similar extent as reported for deprenyl.
Runge I; Horowski R
J Neural Transm Park Dis Dement Sect; 1991; 3(4):273-83. PubMed ID: 1772580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
